［1］中華醫學會血液學分會白血病淋巴瘤學組.成人急性髓系白血病(非急性早幼粒細胞白血病)中國診療指南(2017年版).中華血液學雜志，2017，38 (3): 177-182.

［2］ ARBER DA, ORAZI A, HASSERJIAN R, et al. The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia. Blood, 2016 May19, 127 (20): 2391-2405.

［3］ NCCN clinical practice guidelines in oncology acute myeloid leukemia. Version 1. 2019. http: //www. nccn. org.

［4］ MI Y, XUE Y, YU W, et al. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype. Leuk Lymphoma, 2008 Mar, 49 (3): 524-530.

［5］ D?HNER H, ESTEY E, GRIMWADE D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2016 Nov 28. pii: blood-2016-08-733196. [Epub ahead of print].

［6］ FERNANDEZ HF, SUN Z, YAO X, et al. Anthracycline dose intensi fi cation in acute myeloid leukemia. N Engl J Med, 2009, 361: 1249-1259.

［7］ BURNETT AK, RUSSELL NH, HILLS RK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood, 2015, 125: 3878-3885.

［8］ LIU J, MI Y, FU M, et al. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia. Am J Hematol, 2009 Jul, 84 (7): 422-427.

［9］ JIN J, WANG JX, CHEN FF, et al. Homoharringtonine-based induction regimens for patients with denovo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol, 2013 Jun, 14 (7): 599-608.

［10］ MAYER RJ, DAVIS RB, SCHIFFER CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med, 1994 Oct 6, 331 (14): 896-903.

［11］ BURNETT AK, RUSSELL NH, HILLS RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol, 2013 Sep 20, 31 (27): 3360-3368.

［12］秘營昌，卞壽庚，薛艷萍，等.急性髓系白血病完全緩解后治療周期的初步探討.中華血液學雜志，2001，22 (10): 520-523.

［13］ KORETH J, SCHLENK R, KOPECKY KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in fi rst complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA, 2009 Jun 10, 301 (22): 2349-2361.

［14］ YANG X, WANG J. Precision therapy for acute myeloid leukemia. J Hematol Oncol, 2018 Jan 5, 11 (1): 3.